Horizon Therapeutics (HZNP) Announces New UPLIZNA Data in People With Neuromyelitis Optica Spectrum Disorder to be Presented at AAN's 73rd Annual Meeting

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data will be presented at the American Academy of Neurology’s 73rd Annual Meeting, which will be held virtually April 17-22, 2021. UPLIZNA is the first and only FDA-approved B-cell depleter for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD.

UPLIZNA data being presented at AAN 2021 include:

• Inebilizumab Treatment Reduces the Occurrence of Pain in NMOSD Patients
  • Session: P2.017, H. Kim
  • Date: On Demand (scientific poster)

• Long-Term Efficacy Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial
  • Session: P15.076, B. Cree
  • Date: On Demand (scientific poster)

• Long-Term Safety Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial
  • Session: P15.100, B. Cree
  • Date: On Demand (scientific poster)

• Evaluation of Infusion Reactions and Infusion Times in the N-MOmentum Study of Inebilizumab for NMOSD
  • Session: P15.211, M. Tullman
  • Date: On Demand (scientific poster)

• Pharmacodynamic Modeling and Exposure-Response Assessment of Inebilizumab in Subjects With Neuromyelitis Optica Spectrum Disorder
  • Session: S29.003, L. Yan
  • Date: Wednesday, April 21, 2021, 4:24 p.m. ET (live broadcast)

Additional data highlighting NMOSD patient perspectives being presented at AAN 2021 include:

• Patient Attitudes Towards NMOSD Diagnosis and Treatment: Final Survey Results
  • Session: P2.106, G. Garcia
  • Date: On Demand (scientific poster)

In addition, Horizon will host two Industry Therapeutic Updates. The first is on Tuesday, April 20, 2021 at 1 p.m. ET called “Advances in NMOSD Treatment: Inebilizumab-cdon,” featuring Adil Javed, M.D. Ph.D., associate professor of neurology, University of Chicago. The second is on Wednesday, April 21, 2021 at 9 a.m. ET called “B Cell Biology in Myasthenia Gravis: From Pathogenesis to Targeted Therapies.”

About Neuromyelitis Optica Spectrum Disorder (NMOSD)

NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes. NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord and brain stem.1,2 Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies.3 These AQP4 autoantibodies are produced by CD19+ B cells and bind primarily to astrocytes in the central nervous system.4 Binding of AQP4 antibodies to central and peripheral nervous system cells is believed to trigger attacks, which can damage the optic nerve, spinal cord and brain.4,5 Loss of vision, paralysis, loss of sensation, bladder and bowel dysfunction, nerve pain and respiratory failure can all be manifestations of the disease.6 Each NMOSD attack can lead to further damage and disability.2,7,8 NMOSD occurs more commonly in women and may be more common in individuals of African and Asian descent.9,10

You May Also Be Interested In

• Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• Travere Therapeutics (TVTX) and CSL Vifor Announce EU Approval of FILSPARI